4.6 Article

Improving Awareness, Identification, and Management of Meibomian Gland Dysfunction

Journal

OPHTHALMOLOGY
Volume 119, Issue 10, Pages S1-S12

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ophtha.2012.06.064

Keywords

-

Categories

Funding

  1. The New York Eye and Ear Infirmary
  2. MedEdicus LLC
  3. Alcon, Inc
  4. Bausch & Lomb Incorporated
  5. Santen Pharmaceutical Co, Ltd.

Ask authors/readers for more resources

Ocular surface disorders-and dry eye, in particular-is a leading reason for visits to eye care professionals. It has been generally accepted that meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye, as well as being associated with aqueous-deficient dry eye. Yet, researchers and clinicians have lacked a global consensus on the definition of MGD, its epidemiology, pathophysiology, and management. Various systemic diseases and medications have been associated with the progression of both dry eye and MGD, as have several ocular disorders beyond those directly affecting the surface. It is in the best interest of patients for clinicians to be able to better identify and diagnose MGD, differentiating it from other ocular surface disorders, and to recognize the effects of MGD on the ocular surface, and thus initiate appropriate therapy. This CME activity provides expert insight into the Tear Film and Ocular Surface Society's International Workshop on MGD consensus report, offering practical application of its findings to better manage MGD patient care, particularly for those patients facing or undergoing ocular surgery. Ophthalmology 2012;119:S1-S12 (c) 2012 by the American Academy of Ophthalmology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available